{
    "medicine_id": "c0c6d09e9a0c1733619005534d0eb94d58274d6d",
    "platform_id": "DB10772",
    "metadata": {
        "name": "Gintuit Cellular sheet",
        "composition": "Foreskin keratinocyte neonatal",
        "clinical_particulars": {
            "therapeutic_indications": "For chronic leg ulcers and diabetic foot L2439 Orcel is indicated for use with standard therapeutic compression for the treatment of non infected partial and full thickness skin ulcers due to venous insufficiency of greater than 1 month in duration and which have not effectively responded to conventional ulcer therapy Orcel is also for use with standard diabetic foot ulcer care for the treatment of full thickness neuropathic diabetic foot ulcers of greater than 3 weeks in duration which have not effectively responded to conventional ulcer therapy and which extend through the dermis but without tendon muscle capsule or bone involvement L2459",
            "contraindications": {
                "disease": "Adverse events in a preclinical study of about 300 subjects were classified as mild moderate severe or life threatening In the venous leg ulcer study 1 life threatening infection and 3 severe infections reported in the Apligraf group occurred and none in the control group Of the 4 events 2 severe infections were related to treatment however one occurred one month after the last application of Apligraf and the other occurred following application on a pre existing Pseudomonas infection L2461",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Foreskin keratinocyte grafts lead to the re epithelialization of partial deep severe burns thus allowing complete wound closure and improves the condition of scars L2454",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}